Back to search results

Cemiplimab for Early-Stage Non-Small Cell Lung Cancer

This study is looking into a new way to treat early-stage non-small cell lung cancer (NSCLC) that is 2 to 3.9 centimeters in size. Researchers are testing a drug called cemiplimab along with standard chemotherapy (carboplatin + pemetrexed/paclitaxel, or cisplatin). The goal is to see if this combination can completely get rid of the cancer before surgery. You might be able to join if you are between 18 and 80 years old, have NSCLC that meets specific size and other criteria, and have certain markers like PD-1 or PD-L1. The study will measure how many patients have a complete response to treatment over 5.5 years. The current enrollment status is unclear.

Study design
This is an interventional study planning to enroll 38 participants. It will investigate the ability of cemiplimab-chemotherapy to induce pathologic complete responses.
What's involved
Participants will receive 3 cycles of cemiplimab and chemotherapy, administered every 21 days as an intravenous infusion.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed to measure the pathologic complete response rate for 5.5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07720167

Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer

Not Yet Recruiting
PHASE2Ages 18–80InterventionalTreatment
Medical University of South Carolina
~38 participants
Updated 2026-07-22 on ClinicalTrials.gov
What's tested:CemiplimabCarboplatin + Pemetrexed/PaclitaxelCisplatin

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Frequency and percentage of patients with a pathologic complete response (pCR) rate
Measured over 5.5 years

Conditions

Non-Small Cell Lung Cancer

Explore related trials

Lung Non-Small Cell Carcinoma

Where it's being run

1 sites across 1 states
South Carolina1

Who to contact

HCC Clinical Trials Office
[email protected]
843-792-9321
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

WOCBP are defined as women who are fertile following menarche until becoming postmenopausal, unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy.
Periodic abstinence (calendar, symptothermal, post-ovulation methods), withdrawal (coitus interruptus), spermicides only, and lactational amenorrhea method are not acceptable methods of contraception. Female condom and male condom should not be used together.

What this trial measures

  • Frequency and percentage of patients with a pathologic complete response (pCR) rate5.5 years

    defined as the rate of ypT0N0 stage disease based on AJCC and UICC staging systems